Stockholm, July 11, 2023 - Intervacc AB (publ) announces the initiation of a project with Testa Center, Uppsala, to optimise the development of manufacturing processes for a prototype vaccine in pigs.
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH ... Read more
Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 7 June 2023, at which the following resolutions were made.
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH ... Read more
Stockholm, May 17th, 2023 - The European Medicines Agency (EMA) has, after reviewing stability data, approved the extension of the shelf life for Strangvac®, to 33 months from previously 24 ... Read more